Another earlier memantine trial – the Benefit and Efficacy in Severely Demented patients during Treatment with Memantine (M-Best or 9403) study – enrolled participants with moderately severe AD as ...

Alzheimer's disease is the world's most common neurodegenerative disease, affecting more than 50 million people globally. Alzheimer's disease is also among the most fatal, landing as one of the top ...

Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle ...

For decades, dementia, especially Alzheimer’s disease, was treated as untouchable. Families watched loved ones fade, doctors could offer only reassurance and coping strategies, and research seemed to ...

Together with British colleagues, Russian scientists proposed to treat severe and fatal disease known as spinocerebellar ataxia with memantine, a drug currently used for Alzheimer's disease. The drug ...

Some people with autism spectrum disorder (ASD) have abnormal levels of glutamate in the brain. New research led by Mass General Brigham focused on this neuron-activating chemical, suggesting that a ...

The dementia drug memantine showed promise for improving social functioning in a small trial of youth with autism. Nine of 16 children and adolescents treated with memantine met the response criteria ...

A class of drugs commonly used to treat Alzheimer’s disease and other dementias in nursing home residents has been found to slow cognitive decline over a five-year period in patients diagnosed with ...

Elevated pregenual anterior cingulate cortex levels were associated with a favorable treatment response. HealthDay News — Memantine improves social impairments in youth with autism spectrum disorder ...

Please provide your email address to receive an email when new articles are posted on . Response rates on the SRS-2 and CGI-S were significantly higher in those given memantine. Memantine was also ...

The method used to evaluate medication efficacy in clinical trials in AD has been evolving over the last 10 years and is on the brink of further change. In the past, efficacy assessments have ...